Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease.

Journal Article

Tumor necrosis factor alpha (TNF-α) has both positive and negative roles in human disease. In certain cancers, TNF-α is infused locally to promote tumor regression, but dose-limiting inflammatory effects limit broader utility. In autoimmune disease, anti-TNF-α antibodies control inflammation in most patients, but these benefits are offset during chronic treatment. TAK1 acts as a key mediator between survival and cell death in TNF-α-mediated signaling. Here, we describe Takinib, a potent and selective TAK1 inhibitor that induces apoptosis following TNF-α stimulation in cell models of rheumatoid arthritis and metastatic breast cancer. We demonstrate that Takinib is an inhibitor of autophosphorylated and non-phosphorylated TAK1 that binds within the ATP-binding pocket and inhibits by slowing down the rate-limiting step of TAK1 activation. Overall, Takinib is an attractive starting point for the development of inhibitors that sensitize cells to TNF-α-induced cell death, with general implications for cancer and autoimmune disease treatment.

Full Text

Duke Authors

Cited Authors

  • Totzke, J; Gurbani, D; Raphemot, R; Hughes, PF; Bodoor, K; Carlson, DA; Loiselle, DR; Bera, AK; Eibschutz, LS; Perkins, MM; Eubanks, AL; Campbell, PL; Fox, DA; Westover, KD; Haystead, TAJ; Derbyshire, ER

Published Date

  • August 2017

Published In

Volume / Issue

  • 24 / 8

Start / End Page

  • 1029 - 1039.e7

PubMed ID

  • 28820959

Electronic International Standard Serial Number (EISSN)

  • 2451-9456

International Standard Serial Number (ISSN)

  • 2451-9456

Digital Object Identifier (DOI)

  • 10.1016/j.chembiol.2017.07.011

Language

  • eng